Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
Zacks.com on MSN2d
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...
The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.
Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
"We are delighted with Eli Lilly's decision to establish its Digital Health Innovation Hub in Singapore. This will strengthen ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback